Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Moderna shares fell about 7% on Wednesday without an obvious company-specific catalyst, even as Wolfe Research reiterated a more optimistic view. The move renews scrutiny of how much investors are paying for future revenue growth after a sharp run-up this year.
THE APEX TIMES
THE APEX TIMES
A new market outlook study published via Globe Newswire projects growth in mRNA therapeutics driven by oncology and rare-disease development efforts, delivery-technology advances, and partnerships, profiling Moderna alongside peers including BioNTech and CureVac.
THE APEX TIMES
The company agreed a new research and collaboration deal with BioArctic, aiming to use the Swedish biotech’s BrainTransporter technology in a potential Alzheimer’s treatment, according to a report on Yahoo Finance.
THE APEX TIMES
A new analysis discussed in market coverage found monthly healthcare costs declined over time for adults over 55, with results suggesting reductions of up to 38 percent among those using Zepbound. The researchers said the models did not include the cost of Zepbound itself.
THE APEX TIMES
A market outlook highlighted growth drivers including aging populations, demand for less invasive and drug-free care, and technology shifts such as pulsed field ablation, advanced cardiac mapping tools, and left atrial appendage closure devices.
THE APEX TIMES
A report says hedge fund billionaire David Tepper sold all of his UnitedHealth position during the second quarter. The move could be a routine portfolio adjustment, a valuation call, or a risk-management step, but the public record described in the article does not offer clear guidance on motive.
THE APEX TIMES
Eli Lilly reported results from a real-world study suggesting that people who remained on Zepbound (tirzepatide) for weight management saw lower healthcare costs than those who discontinued, in a population of adults over 55 with overweight or obesity.
THE APEX TIMES
A new market segment discussion tied renewed investor interest in Moderna to a trial framed as a breakthrough, alongside broader healthcare momentum and the increased presence of AI in biotech headlines.
THE APEX TIMES
An analyst upgrade to a peer-to-peer view triggered a market bounce in Moderna, but the note leaves open whether there is additional upside beyond expectations.
